Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

View Full Paper
Ask AI
Bookmark
Share

Authors

GFGeorg‐Nikolaus FrankeTHTobias A.W. HolderriedJVJurjen Versluis

Discussion

Loading...

Member takes

Overview

Analysis shows that venetoclax combined with hypomethylating agents enhances remission rates in relapsed acute myeloid leukemia after stem cell transplant, indicating new salvage potential.

Key Points

  • Cumulative incidence of complete remission post salvage was 44% with HMA/VEN compared to 26% with HMA.
  • Two-year overall survival rates were 24% in the HMA/VEN group and 16% in the HMA group, with significance in late relapses.
  • Patients receiving HMA/VEN had longer median time to relapse post transplant than those receiving HMA alone.
  • HMA and HMA/VEN therapies offer potential long-term survival benefits, especially for those with late relapse and favorable cytogenetics.

Cite This Study

Franke et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b2https://doi.org/10.1182/blood-2025-6079
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database2025
  2. 2Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)2025
  3. 3Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes2025
  4. 4Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations
  5. 5Venetolax plus azacitidine is effective maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with intermediate/high-risk Acute Myeloid Leukemia2025